Year 2020 Vol. 28 No 3




South Ural State Medical University 1, Chelyabinsk,
Institute of Molecular and Cellular Biology of Siberian Branch of RAS 2, Novosibirsk,
JSC ''Vector-Best'' 3, Novosibirsk,
The Russian Federation

Objective. To assess the possibility of a molecular genetic classifier in the preoperative thyroid cancer diagnosis using colored cytological preparations obtained during fine needle aspiration biopsy of thyroid nodes.
Methods. The results of cytological, histological and molecular genetic studies of patients (n=138) were compared. To conduct a molecular genetic study, colored glasses with cytological material from the thyroid nodes of patients were selected, the preoperative cytological conclusions corresponding to the classification of Bethesda (2017) group IV, V, and VI. All patients were operated on at the Regional Center of the Endocrine Surgery or the Regional Oncology and Nuclear Medicine Clinical Center in Chelyabinsk, where a final histological diagnosis was made. To determine agreement of preoperative cytological and postoperative histological conclusions the specimens were divided into 4 groups: a benign node; a follicular tumor without malignancy markers; papillary cancer; and a follicular tumor with malignancy markers.
Results. In thyroid cancer, the coincidence of the results of the preoperative molecular genetic and postoperative histological studies was found in 53 (94.6%) cases (a true positive result), and a discrepancy in 10 (7.2%) (a false positive result). In 72 (52.2%) cases in benign tumors, no molecular genetic markers of malignancy were detected (a true negative result), in 3 (2.2%) cases the cancer was missed (a false negative result).
The prognostic value of a positive result of a molecular genetic study was 84.1%, and the prognostic value of a negative result 96%.
Conclusions. Molecular genetic testing using commonly prepared colored smears can determine accurately the malignant and benign thyroid nodules, thereby it lets improving the quality of pre-operative differential diagnosis of the thyroid nodules and reduce the number of unreasonable operations.

Keywords: thyroid cancer, fine needle aspiration biopsy, molecular genetic study, micro-RNA, Bethesda classification
p. 284-289 of the original issue
  1. Beltsevich DG, Vanushko VE, Rumiantsev PO, Melnichenko GA, Kuznetsov NS, Abrosimov AYu, Polyakov VG, Mudunov AM, Podvyaznikov SO, Romanov IS, Polyakov AP, Sleptsov IV, Chernikov RA, Vorobyov SL. Fadeyev VV. 2017. Russian clinical practice guidelines for differentiated thyroid cancer diagnosis and treatment. Endokrin Khirurgiia. 2017;11(1):6-27. (In Russ.)
  2. Ali S, Cibas E, eds. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes. 2nd ed. New York: Springer; 2018.
  3. Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer. 2007 Oct 25;111(5):306-15. doi: 10.1002/cncr.22955
  4. Wormald R, Sheahan P, Rowley S, Rizkalla H, Toner M, Timon C. Hemithyroidectomy for benign thyroid disease: who needs follow-up for hypothyroidism? Clin Otolaryngol. 2008 Dec;33(6):587-91. doi: 10.1111/j.1749-4486.2008.01794.x
  5. Stoll SJ, Pitt SC, Liu J, Schaefer S, Sippel RS, Chen H. Thyroid hormone replacement after thyroid lobectomy. Surgery. 2009 Oct;146(4):554-8; discussion 558-60. doi: 10.1016/j.surg.2009.06.026
  6. Vargas-Salas S, Martínez JR, Urra S, Domínguez JM, Mena N, Uslar T, Lagos M, Henríquez M, González HE. Genetic testing for indeterminate thyroid cytology: review and meta-analysis. Endocr Relat Cancer. 2018 Mar;25(3):R163-R77. doi: 10.1530/ERC-17-0405
  7. Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB, McIver B. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid. 2012 Oct;22(10):996-1001. doi: 10.1089/thy.2012.0180
  8. Titov SE, Ivanov MK, Karpinskaya EV, Tsivlikova EV, Shevchenko SP, Veryaskina YA, Akhmerova LG, Poloz TL, Klimova OA, Gulyaeva LF, Zhimulev IF, Kolesnikov NN. miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors. BMC Cancer. 2016 Mar 9;16:201. doi: 10.1186/s12885-016-2240-2
  9. Titov S, Demenkov PS, Lukyanov SA, Sergiyko SV, Katanyan GA, Veryaskina YA, Ivanov MK. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.J Clin Pathol. 2020 Mar 25:jclinpath-2020-206445. doi: 10.1136/jclinpath-2020-206445
  10. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009 Nov;19(11):1159-65. doi: 10.1089/thy.2009.0274
Address for correspondence:
454092, Russian Federation,
Chelyabinsk, Vorovskii str., 64,
South Ural State Medical University,
the Department of General
and Pediatric Surgery,
tel. +7 950 744-45-95,
Lukyanov Sergey A.
Information about the authors:
Lukyanov Sergey A., PhD, Assistant, the Department of General and Pediatric Surgery, South Ural State Medical University, Chelyabinsk, Russian Federation.
Sergiyko Sergey V., MD, Associate Professor, Head of the Department of General and Pediatric Surgery, South Ural State Medical University, Chelyabinsk, the Russian Federation.
Titov Sergei E., PhD, Senior Researcher of the Laboratory of the Molecular Genetics, Institute of Molecular and Cellular Biologyof Siberian Branch of RAS, JSC Vector-Best, Novosibirsk, Russian Federation.
Veryaskina Yuliya A., PhD, Researcher of the Laboratory of the Molecular Genetics, Institute of Molecular and Cellular Biology of Siberian Branch of RAS Novosibirsk, Russian Federation.
Contacts | ©Vitebsk State Medical University, 2007-2023